| Company Name: |
Hangzhou Peptidego Biotech Co.,Ltd.
|
| Tel: |
0571-87213919 |
| Email: |
Eric@peptidego.com |
| Products Intro: |
Product Name:Cys-Ala-Glu-Lys
CAS:2088281-24-5
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
| Company Name: |
Hangzhou Sinoda Pharmaceutical Technology Co. LTD
|
| Tel: |
0571-87213919 17306812703 |
| Email: |
3007955328@qq.com |
| Products Intro: |
Product Name:Cys-Ala-Glu-Lys
CAS:2088281-24-5
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
|
| | CAQK peptide Basic information |
| | CAQK peptide Chemical Properties |
| Boiling point | 913.554±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.299±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | form | Solid | | pka | 3.271±0.10(predicted) | | color | White to off-white |
| | CAQK peptide Usage And Synthesis |
| Uses | CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier[1][2]. | | in vivo | CAQK (100 nmoles/100 μL into the tail vein; at 24 h or 5 days post-injury) homes to lysolecithin-induced focal lesions in the spinal cord. | Animal Model: | C57BL/6J 8-week-old male mice[1] | | Dosage: | 100 nmoles/100 μl in PBS | | Administration: | Tail vein; at 24 h or 5 days post-injury (focal demyelination was induced by stereotaxic injection of 1 μL of 1% lysolecithin solution into the right ventral) | | Result: | Caused the accumulation of peptide at the injury site by an increased density of mononucleated DAPI+ cells and fragmented myelin stained for myelin basic protein.
The peptide was not detected in the spinal cords of control sham-operated (PBS injected) mice showing regular densities of DAPI+ cells.
|
| | References | [1] Charly Abi-Ghanem, et al. CAQK, a peptide associating with extracellular matrix components targets sites of demyelinating injuries. Front Cell Neurosci. 2022 Aug 22:16:908401. DOI:10.3389/fncel.2022.908401
[2] Aman P Mann, et al. A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. Nat Commun. 2016 Jun 28:7:11980. DOI:10.1038/ncomms11980 |
| | CAQK peptide Preparation Products And Raw materials |
|